ArticleNature communications2022

Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.

Zhi Qi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.